Valeant’s Higher Bid Seals The Deal With Salix, Ending Endo’s Quest

Valeant raised its offer to buy the GI specialist from $158 to $173 per share in cash; Salix’s board of directors accepted the revised offer, ending a bid by Endo to buy the company.